ArticleMolecules (Basel, Switzerland)2011
The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats.
Article in Molecules (Basel, Switzerland), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 169 citations in OpenAlex.
- Protective effects of silymarin on preventing vancomycin nephrotoxicity in infectious patients: a randomized, double-blinded, placebo-controlled, pilot clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2025Trial
- Nutraceuticals for Preventing and Managing Cancer Chemotherapy-Induced Cardiotoxicity: An Updated Comprehensive Review.Cardiology research and practice · 2026Review
- Aegeline improves doxorubicin-induced liver toxicity by modulating oxidative stress and Bax/Bcl2/caspase/NF-κB signaling.Scientific reports · 2025Article
- Integrative investigation on Hippocratea africana root: insights from cardio-protective, anti-oxidative stress activities, isolation, GC/MS, and pharmacological significance profiling.BMC complementary medicine and therapies · 2025Article
- Protective effects of Alamandine against doxorubicin-induced liver injury in rats.BMC pharmacology & toxicology · 2025Article
- Dietary silymarin supplementation enhances chemotherapy efficacy of capecitabine and irinotecan and mitigates hepatotoxicity in a mouse model of colon cancer.Research in pharmaceutical sciences · 2025Article
- Mechanistic Insights into Flavonoid Subclasses as Cardioprotective Agents Against Doxorubicin-Induced Cardiotoxicity: A Comprehensive Review.Drug design, development and therapy · 2025Review
- Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications.Frontiers in pharmacology · 2025Review
- Dual functions of silibinin in attenuating aortic dissection via regulating iron homeostasis and endoplasmic reticulum stress against ferroptosis.Cell death & disease · 2024Article
- The Effect of Silymarin on the Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting.Brazilian journal of cardiovascular surgery · 2024Article
- Role of diosmin in preventing doxorubicin-induced cardiac oxidative stress, inflammation, and hypertrophy: A mechanistic approach.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Protective effects of arbutin against doxorubicin-induced cardiac damage.Molecular biology reports · 2024Article
- Cardioprotective and Hepatoprotective Potential of Silymarin in Paracetamol-Induced Oxidative Stress.Pharmaceutics · 2024Article
- The Effects of Silymarin on Calcium Chloride-Induced Arrhythmia in Male Rat.Oxidative medicine and cellular longevity · 2024Article
- Taurine Protects Doxorubicin-Induced Hepatotoxicity via Its Membrane-Stabilizing Effect in Rats.Life (Basel, Switzerland) · 2023Article
- Preventive and therapeutic use of herbal compounds against doxorubicin induced hepatotoxicity: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity.Cancer cell international · 2023Review
- Phytochemical analysis and nephroprotective potential of Ajwa date in doxorubicin-induced nephrotoxicity rats: Biochemical and molecular docking approaches.Food science & nutrition · 2023Article
- Phytochemical Profiles and Biological Studies of Selected Botanical Dietary Supplements Used in the United States.Progress in the chemistry of organic natural products · 2023Article
- Trained immunity in monocyte/macrophage: Novel mechanism of phytochemicals in the treatment of atherosclerotic cardiovascular disease.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silymarin is a complex of five major compounds, and silibinin is the most biologically active component of the complex. The aim of this study was to investigate, evaluate and confirm the potential cardioprotective and hepatoprotective effects of administration of silymarin, rich in silibinin, at a dose of 60 mg/kg orally for a time-span of 12 days on doxorubicin induced toxicity in male Wistar rats. The in vivo model was used to explore whether silymarin could prevent damage of liver and heart tissue induced by doxorubicin administered every other day at dose of 1.66 mg/kg intraperitoneally for twelve days. In the study the change of body weight, ECG changes, biochemical parameters of oxidative stress, serum activity of alanine and aspartate transaminase, lactate dehydrogenase, creatine kinase and histological preparations of heart and liver samples of treated animals were examined. According to physiological, pharmacological, microscopic and biochemical results, we confirmed that at the examined dose, silymarin exhibits a protective influence on the heart and liver tissue against toxicity induced by doxorubicin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.